Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by
the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the …

Within the past 10 years, treatment and diagnostic guidelines for nontuberculous
mycobacteria have been recommended by the American Thoracic Society (ATS) and the …

Tuberculosis (TB) chemotherapy started in the 1930s with the discovery by Domagk and
colleagues of the anti‐TB activity of sulfonamides. Since these compounds were very toxic …

For decades after its introduction, the mechanisms of action of the front‐line antituberculosis
therapeutic agent isoniazid (INH) remained unclear. Recent developments have shown that …

Tuberculosis is today amongst the worldwide health threats. As resistant strains of
Mycobacterium tuberculosis have slowly emerged, treatment failure is too often a fact …

Isoniazid (INH) is one of the most efficient drugs for the treatment of Mycobacterium
tuberculosis infections. Despite its rather simple chemical structure, the mechanism by which …

Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of
action is still controversial. Using specialized linkage transduction, a single point mutation …

The ability of Mycobacterium tuberculosis (Mtb) to resist and tolerate antibiotics complicates
the development of improved tuberculosis (TB) chemotherapies. Here we define the Mtb …

The modern age of drug discovery, which had been slowly gathering momentum during the
early part of the twentieth century, exploded into life in the 1940s with the isolation of …

Tuberculosis (TB) claims a life every 10 seconds and global mortality rates are increasing
despite the use of chemotherapy. But why have we not progressed towards the eradication …